France· FR:64849607
JEMPERLI 500 mg, solution à diluer pour perfusion
A medicinal product containing dostarlimab, registered in France by GLAXOSMITHKLINE TRADING SERVICES (IRLANDE).
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- DOSTARLIMAB
- Manufacturer
- GLAXOSMITHKLINE TRADING SERVICES (IRLANDE)
- Country
- France (FR)
- ATC code
- —
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip1334009550808621 flacon(s) en verre de 10 ml
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Dostarlimab in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandJEMPERLIGlaxoSmithKline Trading Services Limited
- SpainJEMPERLI 500 mg CONCENTRADO PARA SOLUCION PARA PERFUSIONGlaxosmithkline Trading Services Limited
- SwitzerlandJemperli
- CzechiaJEMPERLIGlaxoSmithKline Trading Services Limited, Dublin
- United KingdomJemperli 500mg/10ml concentrate for solution for infusion vialsGlaxoSmithKline UK Ltd
- IrelandJEMPERLI 500 mg concentrate for solution for infusionGlaxoSmithKline Trading Services Limited
- IcelandJemperliGlaxoSmithKline Trading Services Limited
- NetherlandsJemperli 500 mg oplossing voor infusieGlaxoSmithKline Trading Services Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Jemperli
- Liechtenstein · Jemperli
- Norway · Jemperli
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9bd412d4-0e9c-4a33-b458-ec23260656ce GET /v1/drugs/9bd412d4-0e9c-4a33-b458-ec23260656ce?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "64849607",
"date_amm": "2021-04-21",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/21/1538",
"substance": "DOSTARLIMAB",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "solution à diluer pour perfusion",
"voies_administration": "intraveineuse",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about dostarlimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.